Hanlim & Korean Government Fund Pathway to Clinical Trial

• Non-Dilutive Funding: Hanlim, partially supported by a grant from the South Korean Government’s Korea Drug Development Fund (KDDF), will fund preparatory work needed to start an Australian clinical trial using intravenously administered (IV) HL270 (INV043) on oesophageal cancer. • Two-Stage Development Program: The total value of the work program is estimated to be worth up to ~A$2M and will be